TY  - JOUR
T1  - DUal antiplatelet therapy and the risk of bleeding—reply
AU  - Hansen M, Gislason G, Torp-Pedersen C
Y1  - 2011/04/25
N1  - 10.1001/archinternmed.2011.148
JO  - Archives of Internal Medicine
SP  - 782
EP  - 790
VL  - 171
IS  - 8
N2  - 
First, dual aspirin and clopidogrel should not be a treatment regime on patients who do not receive OAC therapy due to bleeding risk. The bleeding risk with dual aspirin and clopidogrel therapy is at best comparable to what is seen with OAC therapy. This was shown in the ACTIVE W trial, which also taught us that to obtain protection against stroke, you need OAC therapy.2

SN  - 0003-9926
M3  - doi: 10.1001/archinternmed.2011.148
UR  - http://dx.doi.org/10.1001/archinternmed.2011.148
ER  -